Scaling-Up hPSC-Derived Cardiomyocytes for Preclinical and Therapeutic Applications
Join our live webinar to learn best practices for scalable hPSC-derived cardiomyocyte workflows.
Cardiovascular diseases, particularly heart failure, are leading causes of morbidity and mortality worldwide, driven largely by damage to the ventricular muscle. As cell replacement therapies advance, human pluripotent stem cell (hPSC)-derived cardiomyocytes offer great potential for repairing diseased or damaged heart tissue.
In this webinar, Dr. Vincenzo Macri will introduce a scale-up workflow using the STEMdiff™ Cardiomyocyte Expansion Kit, which enables the production of over 600 million hPSC-derived ventricular cardiomyocytes in just 30 days. The presentation will begin with an overview of the global burden of heart disease, focusing on heart failure and ventricular muscle pathology. It will then transition into the potential of cell therapies, specifically highlighting the role of hPSC-derived cardiomyocytes in repairing ventricular damage.
Attendees will also learn about the tools and products available to support hPSC-derived cardiomyocyte workflows, including detailed data on cell phenotyping (flow cytometry and RNA sequencing) and functional assessments (MEA electrophysiology). Additionally, the webinar will showcase a simple scale-up protocol using the STEMdiff™ Cardiomyocyte Expansion Kit, emphasizing its ease of use and robust cell output, making it ideal for pre-clinical models, including large animal studies.
Latest Posts
